Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism

[1]  Dosenko VIe,et al.  Role of apoptosis in the pathogenesis of atherosclerosis , 2000 .

[2]  G. Lenzi,et al.  Increased expression of dopamine receptors on lymphocytes in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[3]  R. Cacabelos,et al.  Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals , 1999, Journal of Neuroimmunology.

[4]  I. Ziv,et al.  Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity? , 1998, Movement disorders : official journal of the Movement Disorder Society.

[5]  P. Mcgeer,et al.  The role of the immune system in neurodegenerative disorders , 1997, Movement disorders : official journal of the Movement Disorder Society.

[6]  M. Castagna,et al.  T-lymphocyte tumor necrosis factor-α receptor binding in patients with Parkinson's disease , 1997, Journal of the Neurological Sciences.

[7]  P. Mcgeer,et al.  Inflammatory Cytokines in the CNS , 1997 .

[8]  A. Ricci,et al.  Expression of dopamine receptors in immune organs and circulating immune cells. , 1997, Clinical and experimental hypertension.

[9]  M. Castagna,et al.  T-lymphocyte tumor necrosis factor-alpha receptor binding in patients with Parkinson's disease. , 1997, Journal of the neurological sciences.

[10]  E. Robinet,et al.  Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. , 1996, Journal of immunology.

[11]  T. Yanagihara,et al.  Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease , 1996, Neurology.

[12]  M. Calopa,et al.  T cell subsets in multiple sclerosis: a serial study , 1995, Acta neurologica Scandinavica.

[13]  H. Stolze,et al.  Defective production of interleukin-2 in patients with idiopathic Parkinson's disease , 1995, Journal of the Neurological Sciences.

[14]  H. Matsumoto,et al.  A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease , 1995, Journal of the Neurological Sciences.

[15]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[16]  J. Sprent,et al.  Upregulation of surface markers on dying thymocytes , 1995, The Journal of experimental medicine.

[17]  R. Bartrons,et al.  Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion , 1995, Brain Research.

[18]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[19]  V. Kostulas,et al.  Parkinson's disease and immunological abnormalities: increase of HLA‐DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood , 1994, Acta neurologica Scandinavica.

[20]  R. Bartrons,et al.  Stereotaxic Administration of 1‐Methyl‐4‐Phenylpyridinium Ion (MPP+) Decreases Striatal Fructose 2,6‐Bisphosphate in Rats , 1994, Journal of neurochemistry.

[21]  P. Neveu,et al.  Modulation of immune reactivity by unilateral striatal and mesolimbic dopaminergic lesions , 1994, Neuroscience Letters.

[22]  G. Defazio,et al.  Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture , 1994, Brain Research.

[23]  P. Riederer,et al.  Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. , 1994, Neuroscience letters.

[24]  R. Bartrons,et al.  Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+ , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[25]  R. Schnabel,et al.  Antibody-dependent cell-mediated cytotoxicity (ADCC) in Parkinson's disease , 1993, Journal of the Neurological Sciences.

[26]  J. Verdaguer,et al.  Lymphocyte immunophenotyping by flow cytometry in normal adults. Comparison of fresh whole blood lysis technique, Ficoll-Paque separation and cryopreservation. , 1992, Journal of immunological methods.

[27]  J. Griño,et al.  Sequential monitoring of immunoregulatory T cell subsets in renal transplantation. , 1992, Transplantation proceedings.

[28]  B. Snow,et al.  Criteria for diagnosing Parkinson's disease , 1992, Annals of neurology.

[29]  P. Carvey,et al.  The potential use of a dopamine neuron antibody and a striatal‐derived neurotrophic factor as diagnostic markers in Parkinson's disease , 1991, Neurology.

[30]  R. T. Jackson,et al.  Binding of [3H]-dopamine to human lymphocytes: possible relationship to neurotransmitter uptake sites. , 1991, Pharmacology.

[31]  S. Raziuddin,et al.  Immune activation and T cell subset abnormalities in circulation of patients with recently diagnosed type I diabetes mellitus , 1990, Clinical and experimental immunology.

[32]  T. Munsat.  Quantification of neurologic deficit , 1989 .

[33]  H. Weiner,et al.  Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4 + 2H4 +) T Cells in multiple sclerosis , 1988, Annals of neurology.

[34]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[35]  M. Rowley,et al.  Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[36]  N. Letvin,et al.  A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. , 1987, The Journal of clinical investigation.

[37]  R. Maini,et al.  Multiple sclerosis , 1986, Neurology.

[38]  E. Reinherz,et al.  In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. , 1985, The New England journal of medicine.

[39]  M. Feldmann,et al.  The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes. , 1985, Clinical and experimental immunology.

[40]  D. Calne,et al.  Assessment of Parkinson's Disease , 1984, Clinical neuropharmacology.